Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 14Lymphoma, Non-Hodgkin 7Lymphoma, B-Cell 5Lymphoma 3Recurrence 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Hodgkin Disease 2Burkitt Lymphoma 2Neoplasms 1Lymphoma, Mantle-Cell 1Leukemia, Hairy Cell 1Hematologic Neoplasms 1

Interventions

Rituximab 27Lenalidomide 22Cyclophosphamide 20Prednisone 14Vincristine 12obinutuzumab 11Magnetic Resonance Spectroscopy 11Doxorubicin 11Specimen Handling 9Bendamustine Hydrochloride 8ibrutinib 7Biopsy 7pembrolizumab 6fludarabine 6fludarabine phosphate 5Radiotherapy 5Peripheral Blood Stem Cell Transplantation 5zanubrutinib 4venetoclax 4tazemetostat 4Whole-Body Irradiation 4R-CHOP protocol 4Etoposide 4CT-P10 4Prednisolone 3Mycophenolic Acid 3Cyclosporine 3tisagenlecleucel 2polatuzumab vedotin 2orelabrutinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, Follicular × polatuzumab vedotin × 90 days × Clear all
NCT05169658 2026-05-13

Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

University of Washington

Phase 2 Completed
42 enrolled 10 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT04491370 2026-04-15

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

New York Medical College

Phase 1/2 Recruiting
20 enrolled
Lymphoid

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡